153 related articles for article (PubMed ID: 22568510)
1. Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumab.
Linden MA; Bachanova V; Sachs Z; Young JA; Singleton TP; Ustun C
Leuk Lymphoma; 2013 Jan; 54(1):174-6. PubMed ID: 22568510
[No Abstract] [Full Text] [Related]
2. Allogeneic immunity and anti-CD20 therapy: a potent combination in the treatment of a patient with Richter transformation of chronic lymphocytic leukemia.
Tam CS
Leuk Lymphoma; 2013 Jan; 54(1):7-8. PubMed ID: 22680773
[No Abstract] [Full Text] [Related]
3. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD20: tales of identical twins?
Schuh A
Blood; 2011 Nov; 118(19):5066-7. PubMed ID: 22077072
[No Abstract] [Full Text] [Related]
5. Waxing and waning intravascular large cell lymphoma with widespread organ infiltration.
Vos JM; Bordbar A; Vet RJ; Pals ST; Kater AP
Leuk Lymphoma; 2011 Apr; 52(4):705-8. PubMed ID: 21190427
[No Abstract] [Full Text] [Related]
6. [Richter syndrome: report of a case].
Chen DB; Song QJ; Shen DH
Zhonghua Bing Li Xue Za Zhi; 2010 Jul; 39(7):487-8. PubMed ID: 21055184
[No Abstract] [Full Text] [Related]
7. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival.
Khouri IF; Lee MS; Saliba RM; Andersson B; Anderlini P; Couriel D; Hosing C; Giralt S; Korbling M; McMannis J; Keating MJ; Champlin RE
Exp Hematol; 2004 Jan; 32(1):28-35. PubMed ID: 14725898
[TBL] [Abstract][Full Text] [Related]
8. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP
J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276
[TBL] [Abstract][Full Text] [Related]
9. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.
Wierda WG; Padmanabhan S; Chan GW; Gupta IV; Lisby S; Osterborg A;
Blood; 2011 Nov; 118(19):5126-9. PubMed ID: 21856867
[TBL] [Abstract][Full Text] [Related]
10. Follow-up data of 10 patients with B-cell non-Hodgkin lymphoma with a CD20-negative phenotypic change after rituximab-containing therapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):563-70. PubMed ID: 23426122
[TBL] [Abstract][Full Text] [Related]
11. A case of long-term remission with ofatumumab maintenance therapy in multiply relapsed and rituximab-refractory chronic lymphocytic leukaemia with deletion 17p.
Namberger K; Weiss L; Krause B; Melchardt T; Greil R
Eur J Haematol; 2013 Apr; 90(4):349-50. PubMed ID: 23278160
[No Abstract] [Full Text] [Related]
12. Monoclonal antibodies in the treatment of chronic lymphocytic leukemia.
Liu NS; O'Brien S
Med Oncol; 2004; 21(4):297-304. PubMed ID: 15579912
[TBL] [Abstract][Full Text] [Related]
13. Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.
Abuelgasim KA; Rehan H; Alsubaie M; Al Atwi N; Al Balwi M; Alshieban S; Almughairi A
J Med Case Rep; 2018 Mar; 12(1):64. PubMed ID: 29524963
[TBL] [Abstract][Full Text] [Related]
14. rILYd4, a human CD59 inhibitor, enhances complement-dependent cytotoxicity of ofatumumab against rituximab-resistant B-cell lymphoma cells and chronic lymphocytic leukemia.
Ge X; Wu L; Hu W; Fernandes S; Wang C; Li X; Brown JR; Qin X
Clin Cancer Res; 2011 Nov; 17(21):6702-11. PubMed ID: 21918174
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on chronic lymphocytic leukemia: a Pharma Matters report.
D'Souza P; Walker G
Drugs Today (Barc); 2014 Jul; 50(7):485-501. PubMed ID: 25101331
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of diffuse large B-cell lymphoma in a patient with ataxia telangiectasia using rituximab.
Machida S; Tomizawa D; Tamaichi H; Okawa T; Endo A; Imai K; Nagasawa M; Morio T; Mizutani S; Takagi M
J Pediatr Hematol Oncol; 2013 Aug; 35(6):482-5. PubMed ID: 23389503
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment and re-treatment of resistant B-cell chronic lymphocytic leukemia with the monoclonal anti-CD 20 antibody rituximab.
Herold M; Schulze A; Härtwig K; Anger G
Ann Hematol; 2000 Jun; 79(6):332-5. PubMed ID: 10901614
[TBL] [Abstract][Full Text] [Related]
18. [Evidence-based therapy for chronic leukemia].
Okamoto S
Nihon Naika Gakkai Zasshi; 2003 Jun; 92(6):979-85. PubMed ID: 12866442
[No Abstract] [Full Text] [Related]
19. Rituximab for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Hagemeister F
Drugs; 2010 Feb; 70(3):261-72. PubMed ID: 20166765
[TBL] [Abstract][Full Text] [Related]
20. Successful response to rituximab in a patient with pure red cell aplasia complicating chronic lymphocytic leukaemia.
Batlle M; Ribera JM; Oriol A; Plensa E; Millá F; Feliu E
Br J Haematol; 2002 Sep; 118(4):1192-3. PubMed ID: 12199808
[No Abstract] [Full Text] [Related]
[Next] [New Search]
